Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 147, Issue 6, Pages 1803-1811Publisher
SPRINGER
DOI: 10.1007/s00432-020-03458-6
Keywords
Cutaneous squamous cell carcinoma; PD-1; Skin cancer; Immunotherapy; Checkpoint blockade
Categories
Ask authors/readers for more resources
PD-1 inhibition therapy shows durable responses in patients with advanced or metastatic CSCC. Patients should be closely monitored for immune-related adverse events, especially those who are frail or immune-suppressed. Further research on potential biomarkers is needed to identify patients who will benefit the most from this therapeutic option.
Purpose Approximately 5% of patients with cutaneous squamous cell carcinoma (CSCC) may develop recurrent or metastatic disease. The management of such cases is challenging and requires multi-disciplinary care. Immunotherapy using PD-1 inhibition was approved to treat unresectable or metastatic CSCC in 2018. Given limited data regarding clinical outcomes outside of published trials, we describe our experience using this therapy. Methods We retrospectively reviewed all patients treated with PD-1 inhibition as therapy for locally advanced, regionally metastatic or distant metastatic CSCC at the University of Southern California. Clinicopathological characteristics, treatment data using PD-1 inhibitors, and outcomes were assessed. Results Among 26 patients treated with PD-1 inhibition, the objective response rate was 42.3%, with 19.2% of patients having partial response and 23.1% having complete response to therapy. The median progression-free survival was 5.4 months. Median tumor mutational burden (TMB) was higher among responders compared to non-responders (60 vs. 9 Mut/Mb, p = 0.04). Primary CSCC tumor location on the head/neck was also associated with response to PD-1 inhibition (p = 0.04). Two patients with mutations affecting mismatch repair deficiency were noted to have complete response to treatment. No other variables were associated with treatment outcomes. Conclusion PD-1 inhibition produces durable responses among patients with advanced or metastatic CSCC. PD-1 inhibition therapy is well tolerated, but patients should be monitored closely for immune-related adverse events, particularly frail or immune-suppressed patients. Further investigation of potential biomarkers to help identify patients who will derive the most benefit from this therapeutic option is needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available